CFTR and cystic fibrosis: The use of NGS technology for carrier screening seems more promising in small communities with low or unknown CF prevalence than the targeted approach, since NGS can provide comprehensive testing of CFTR variants and obtain information on both known mutations and novel DNA changes in the CFTR gene with high efficiency, thereby maximizing CFTR gene coverage.